Welcome to our book review site go-pdf.online!
You may have to Search all our reviewed books and magazines, click the sign up button below to create a free account.
Multiple Myeloma
Multiple Myeloma: The second issue of Emerging Cancer Therapeutics focuses on multiple myelomas also known as plasma cell myeloma, KahlerÌs Disease and myelomatosis. It is estimated that over 20,000 new cases are diagnosed each year with over 10,000 people dying from these malignancies. Multiple myelomas are highly treatable but rarely curable. Thus it is crucial for the practitioner to be up-to-date on the latest insights regarding their management. Management options and outcomes for individuals with multiple myelomas improved dramatically with the introduction of chemotherapy. Even further improvements in prognosis have occurred because of the introduction of newer therapies such as puls...
Multiple Myeloma
This is a comprehensive, state-of-the-art guide to the diagnosis, treatment, and biology of multiple myeloma and related plasma disorders. Edited and written by a multidisciplinary group of recognized authorities from the Mayo Clinic, it presents clear guidelines on diagnosis and therapy and covers all aspects of multiple myeloma, from molecular classification and diagnosis, to risk stratification and therapy. Closely related plasma cell disorders such as solitary plasmacytoma, Waldenstrom macroglobulinemia, and light chain amyloidosis are discussed in detail as well. The book addresses often overlooked topics, including the role of radiation therapy, vertebral augmentation, and supportive care. Our understanding of this group of disorders is developing at an unprecedented rate, and Multiple Myeloma meets the need among oncologists and hematologists for a clear, timely, and authoritative resource on their biology, diagnosis, and treatment.
Myeloma
None
Advances in Biology and Therapy of Multiple Myeloma
Despite the advances in conventional, novel agent and high dose chemotherapy multiple myeloma (MM) remains incurable. In order to overcome resistance to current therapies and improve patient outcome, novel biologically-based treatment approaches are being developed. Current translational research in MM focusing on the development of molecularly-based combination therapies has great promise to achieve high frequency and durable responses in the majority of patients. Two major advances are making this goal possible. First, recent advances in genomics and proteomics in MM have allowed for increased understanding of disease pathogenesis, identified novel therapeutic targets, allowed for molecula...
Molten Salts and Ionic Liquids
For many years, the related fields of molten salts and ionic liquids have drifted apart, to their mutual detriment. Both molten salts and ionic liquids are liquid salts containing only ions - all that is different is the temperature! Both fields involve the study of Coulombic fluids for academic and industrial purposes; both employ the same principles; both require skilled practitioners; both speak the same language; all then that is truly different is their semantics, and how superficial is that? The editors of this book, recognising that there was so much knowledge, both empirical and theoretical, which can be passed from the molten salt community to the ionic liquid community, and vice ve...
AACR 2017 Proceedings: Abstracts 1-3062
The AACR Annual Meeting highlights the best cancer science and medicine from institutions all over the world. Attendees are invited to stretch their boundaries, form collaborations, attend sessions outside their own areas of expertise, and learn how to apply exciting new concepts, tools, and techniques to their own research. Part A contains abstracts 1-3062 accepted for the 2017 meeting.
Immunomodulating Drugs for the Treatment of Cancer
Immunomodulating Drugs for the Treatment of Cancer provides a comprehensive resource for clinicians and researchers regarding immunomodulatory (IMiDs) drugs and their rapidly emerging role in cancer medicine. This new class of anticancer agents has made a tremendous impact on the treatment of patients with various malignant diseases, including blood cancers and several cancers of the solid organs. Their popularity in prescribing is based on several important characteristics including: (1) oral bioavailability, (2) non-chemotherapeutic, (3) extremely well-tolerated in all age groups, (4) ability to activate patient's own immune response against cancer, (5) ease of combination with other agents such as chemotherapy resulting in higher responses as well as (6) variability of anticancer activity.
PET in the Management of Hematologic Malignancies, An Issue of PET Clinics
This issue of PET Clinics focuses on PET in the Management of Hematologic Malignancies and is edited by Drs. Abass Alavi (the Consulting Editor of PET Clinics), Gary Ulaner, Jakub Svoboda, and Lale Kostakoglu. Articles will include: PET-CR as a surrogate to replace PFS in assessment of efficacy of DLBCL treatments; PET-Derived Quantitative Metrics for Response and Prognosis; Evolving Role of PET Based Novel Quantitative Techniques in the Management of Hematological Malignancies; Critical Role of FDG/NaF imaging in Assessment of Skeletal Involvement in Patients with Multiple Myeloma; Response adapted treatment strategies in Hodgkin lymphoma using PET scans; FDG PET/CT as a staging tool in multiple myeloma; FDG PET/CT as a predictor of prognosis in multiple myeloma; PET/CT as a response evaluation tool in multiple myeloma; PET imaging in CLL and Richter’s transformation; Current Overview and Future Directions of PET for Hematologic Malignancies; and more!
Antiangiogenic Cancer Therapy
Top Investigators Explore the Complexities of Angiogenesis Cancer Research The targeting of tumor angiogenesis has evolved into one of the most widely pursued therapeutic strategies. However, as of yet, no antiangiogenic agent used as a monotherapy has demonstrated a survival benefit in a randomized Phase III trial. The combination of bev
